Clinical, metabolic and molecular biochemistry Team, Faculty of Medicine and Pharmacy, Mohammed V University, 10100 Rabat, Morocco, Higher Institute of Nursing Professions and Health Techniques of Marrakech, annex of Safi, Morocco.
Laboratory of Biostatistics, Clinical Research and Epidemiology, Faculty of Medicine and Pharmacy, Mohammed V University, 10100 Rabat, Morocco.
Ann Biol Clin (Paris). 2023 Jul 21;81(3):280-288. doi: 10.1684/abc.2023.1815.
The Estrogen receptor β (ESR-β) gene is suggested to have a growth inhibitory role in prostate tissue and was proposed as a new therapeutic target for prostate cancer (PCa). Precedent studies have investigated the association between the ESR-β rs1256049 polymorphism and PCa but findings were inconsistent. Thus, this meta-analysis was performed to assess whether the ESR-β rs1256049 polymorphism is associated with an increased susceptibility to PCa. Eligible studies published before February 5, 2022 were systematically searched in PubMed, Web of Science, ScienceDirect and Google Scholar databases. The sample set was extracted from 11 case-control studies involving 9390 cases and 10057 controls for the association between ESR-β rs1256049 polymorphism and PCa susceptibility. In our overall meta-analysis, no significant association between rs1256049 and PCa risk was found under all genetic models. In subgroup analysis according to ethnicity, Asians, had a significantly decreased cancer risk based on both the heterozygote genetic model (OR = 0.75, 95% CI = [0.63, 0.89] P = 0.01) and the dominant model (OR = 0.80, 95% CI [0.69, 0.94] P = 0.01). For the Caucasian group, there was a significantly increased risk observed in the allelic model (OR = 1.17, 95% CI = [1.04, 1.32] P = 0.01), heterozygote model (OR = 1.15, 95% CI = [1.01, 1.31] P = 0.03) and the dominant model (OR = 1.17, 95% CI = [1.03, 1.32] P = 0.01). Our results demonstrate that ESR-β r1256049 polymorphism may play a possible promising effect in PCa in Caucasians and a protective factor in Asians.
雌激素受体β（ESR-β）基因被认为在前列腺组织中具有生长抑制作用，并被提议作为前列腺癌（PCa）的新治疗靶点。先前的研究已经调查了 ESR-β rs1256049 多态性与 PCa 之间的关联，但研究结果不一致。因此，进行了这项荟萃分析，以评估 ESR-β rs1256049 多态性是否与 PCa 的易感性增加相关。在 2022 年 2 月 5 日之前，系统地在 PubMed、Web of Science、ScienceDirect 和 Google Scholar 数据库中搜索了符合条件的研究。从 11 项病例对照研究中提取了样本集，这些研究涉及 9390 例病例和 10057 例对照，以评估 ESR-β rs1256049 多态性与 PCa 易感性之间的关系。在我们的总体荟萃分析中，在所有遗传模型下，rs1256049 与 PCa 风险之间均无显著关联。根据种族进行亚组分析时，亚洲人在杂合子遗传模型（OR=0.75，95%CI=[0.63, 0.89]，P=0.01）和显性模型（OR=0.80，95%CI=[0.69, 0.94]，P=0.01）下，癌症风险显著降低。对于白种人群，在等位基因模型（OR=1.17，95%CI=[1.04, 1.32]，P=0.01）、杂合子模型（OR=1.15，95%CI=[1.01, 1.31]，P=0.03）和显性模型（OR=1.17，95%CI=[1.03, 1.32]，P=0.01）中，观察到风险显著增加。我们的结果表明，ESR-β r1256049 多态性可能在白种人群中的 PCa 中发挥潜在的有利作用，而在亚洲人群中是一种保护因素。
